

## **Product** Data Sheet

Inhibitors

**Screening Libraries** 

**Proteins** 

## **Tilomisole**

Molecular Formula:

Cat. No.: HY-106050
CAS No.: 58433-11-7

Molecular Weight: 342.8


Target: Others

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

 $C_{17}H_{11}CIN_{2}O_{2}S$ 



## **BIOLOGICAL ACTIVITY**

Description

Tilomisole (Wy 18251) is a benzimidazothiazole experimental agent with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation $^{[1][2]}$ .

## **REFERENCES**

[1]. Dillman RO, et al. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients. Mol Biother. 1992;4(1):10-14.

[2]. Darwish SA, et al. New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies [published online ahead of print, 2022 Jan 29]. Bioorg Chem. 2022;120:105644.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA